We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+3.84%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$306M
AUM Growth
+$45.6M
Cap. Flow
+$57.6M
Cap. Flow %
18.83%
Top 10 Hldgs %
85.78%
Holding
34
New
9
Increased
9
Reduced
4
Closed
8

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$16.5M
2
IMMU
Immunomedics Inc
IMMU
+$12.4M
3
FBRX icon
Forte Biosciences
FBRX
+$11.3M
4
ALDR
Alder Biopharmaceuticals
ALDR
+$10.1M
5
BPMC
Blueprint Medicines
BPMC
+$8.48M

Top Sells

Rank Stock Value
1
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$5.78M
2
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$5.75M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$4.44M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$4.17M
5
IRTC icon
iRhythm Holdings
IRTC
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 44.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABEO icon
26
Abeona Therapeutics
ABEO
$343M
$117K 0.04%
+733
New +$100K
ACRS icon
27
Aclaris Therapeutics
ACRS
$744M
– –
-140,000
Closed -$4.17M
IRTC icon
28
iRhythm Holdings
IRTC
$3.86B
– –
-70,010
Closed -$2.63M
NTLA icon
29
Intellia Therapeutics
NTLA
$1.52B
– –
-150,000
Closed -$2.11M
NTRA icon
30
Natera
NTRA
$36.1B
– –
-285,731
Closed -$2.53M
PTGX icon
31
Protagonist Therapeutics
PTGX
$8.8B
– –
-346,281
Closed -$4.44M
JNCE
32
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-91,600
Closed -$2.01M
MNTA
33
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-430,632
Closed -$5.75M
BOLD
34
DELISTED
Audentes Therapeutics, Inc
BOLD
– –
-66,553
Closed -$1.13M
1
2

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q2 2017 Portfolio in Review

As of Q2 2017, Foresite Capital Management III held 34 positions worth $306M, up 17% from $261M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Foresite Capital Management III deployed $57.6M of net new capital in Q2 2017, opening 9 new positions and adding to 9 existing holdings. Its largest new stake was Forte Biosciences: 2,008 shares worth $9.06M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 50% a quarter earlier.

On the sell side, the largest reduction was Bellicum Pharmaceuticals, Inc., an estimated $5.78M trimmed.

  • Foresite Capital Management III's largest Q2 2017 buy was Forte Biosciences: 2,008 shares worth $9.06M.
  • Foresite Capital Management III added most to Aerie Pharmaceuticals in Q2 2017, an estimated $16.5M increase.
  • Foresite Capital Management III's biggest Q2 2017 reduction was Bellicum Pharmaceuticals, Inc., cutting an estimated $5.78M.
  • Foresite Capital Management III fully exited Momenta Pharmaceuticals, Inc. in Q2 2017, selling an estimated $5.75M.
  • Foresite Capital Management III's ten largest holdings make up 86% of its $306M portfolio in Q2 2017.
  • Foresite Capital Management III opened 9 new positions and closed 8 in Q2 2017.
  • Foresite Capital Management III's portfolio value rose 17% quarter-over-quarter to $306M.

Based on Foresite Capital Management III's 13F filing for Q2 2017, filed 14 Aug 2017.